Optiscan has been featured in a Stockhead article, which has also appeared in The Australian, highlighting the commencement of its US breast cancer clinical study at Mayo Clinic evaluating the company’s InVue precision surgery imaging platform and InForm digital pathology platform.

The article notes that patient recruitment is now underway following site initiation, with the 35-patient study designed to generate clinical evidence supporting planned US FDA 510(k) submissions for both devices in the second half of CY2026. The study will evaluate both platforms within a single surgical workflow and will also contribute to the development of Optiscan’s AI and machine learning capabilities for breast cancer tissue assessment.

Managing Director Dr. Camile Farah said: “By evaluating both devices within one clinical workflow, we are building evidence for a potentially integrated surgical-pathology solution that could support faster intraoperative decisions and extend point-of-care tissue assessment into digital pathology.”

Stockhead – Read the full article here.
The Australian – Read the full article here.